2.12
0.03 (1.44%)
| Previous Close | 2.09 |
| Volume | 345,143 |
| Price / Sales | 3.54 |
| Price / Book | 1.85 |
| 52 Weeks Range |
| Operating Margin (TTM) | -41,252.01% |
| Diluted EPS (TTM) | -0.870 |
| Quarterly Revenue Growth (YOY) | 103.60% |
| Total Debt/Equity (MRQ) | 1.00% |
| Current Ratio (MRQ) | 5.28 |
| Operating Cash Flow (TTM) | -47.70 M |
| Levered Free Cash Flow (TTM) | 34.37 M |
| Return on Assets (TTM) | -34.47% |
| Return on Equity (TTM) | -54.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | InflaRx N.V. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.44% |
| % Held by Institutions | 26.24% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |